{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T11:20:11Z","timestamp":1788607211575,"version":"build-2803163510"},"reference-count":83,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T00:00:00Z","timestamp":1746576000000},"content-version":"am","delay-in-days":340,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100017675","name":"William F Vilas Trust Estate","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017675","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG070973"],"award-info":[{"award-number":["R01AG070973"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["R01AG083883"],"award-info":[{"award-number":["R01AG083883"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["P30AG062715"],"award-info":[{"award-number":["P30AG062715"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.jneuroim.2024.578364","type":"journal-article","created":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T15:27:33Z","timestamp":1714750053000},"page":"578364","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Mitigation of CXCL10 secretion by metabolic disorder drugs in microglial-mediated neuroinflammation"],"prefix":"10.1016","volume":"391","author":[{"given":"Sophia F.","family":"Oliai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel C.","family":"Shippy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler K.","family":"Ulland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2024.578364_bb0005","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1001\/jama.2021.3854","article-title":"Evaluation of Aducanumab for Alzheimer disease: scientific evidence and regulatory review involving efficacy, safety, and futility","volume":"325","author":"Alexander","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jneuroim.2024.578364_bb0010","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.3390\/ijms23073785","article-title":"Brain metabolic alterations in Alzheimer\u2019s disease","volume":"23","author":"Ardanaz","year":"2022","journal-title":"IJMS"},{"key":"10.1016\/j.jneuroim.2024.578364_bb0015","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1007\/s11745-999-0478-1","article-title":"Cerebrospinal fluid lipoproteins are more vulnerable to oxidation in Alzheimer\u2019s disease and are neurotoxic when oxidized ex vivo","volume":"34","author":"Bassett","year":"1999","journal-title":"Lipids"},{"key":"10.1016\/j.jneuroim.2024.578364_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.112746","article-title":"\u201cAducanumab\u201d making a comeback in Alzheimer\u2019s disease: an old wine in a new bottle","volume":"148","author":"Behl","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.jneuroim.2024.578364_bb0025","doi-asserted-by":"crossref","DOI":"10.1161\/01.CIR.0000131519.15067.1f","article-title":"Safety of statins: focus on clinical pharmacokinetics and drug interactions","volume":"109","author":"Bellosta","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jneuroim.2024.578364_bb0030","doi-asserted-by":"crossref","first-page":"450","DOI":"10.3390\/metabo10110450","article-title":"Energy metabolism decline in the aging brain\u2014pathogenesis of neurodegenerative disorders","volume":"10","author":"B\u0142aszczyk","year":"2020","journal-title":"Metabolites"},{"key":"10.1016\/j.jneuroim.2024.578364_bb0035","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1148\/rg.343135065","article-title":"Brain PET in suspected dementia: patterns of altered FDG metabolism","volume":"34","author":"Brown","year":"2014","journal-title":"RadioGraphics"},{"key":"10.1016\/j.jneuroim.2024.578364_bb0040","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1517\/14656566.5.12.2573","article-title":"Eplerenone in hypertension","volume":"5","author":"Burgess","year":"2004","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.jneuroim.2024.578364_bb0045","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1016\/S0149-2918(03)80282-5","article-title":"Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension","volume":"25","author":"Burgess","year":"2003","journal-title":"Clin. Ther."},{"key":"10.1016\/j.jneuroim.2024.578364_bb0050","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1139\/cjpp-2016-0710","article-title":"Alteration of high-density lipoprotein functionality in Alzheimer\u2019s disease patients","volume":"95","author":"Camponova","year":"2017","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"10.1016\/j.jneuroim.2024.578364_bb0055","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1186\/1742-2094-9-260","article-title":"Mineralocorticoid and glucocorticoid receptors differentially regulate NF-kappaB activity and pro-inflammatory cytokine production in murine BV-2 microglial cells","volume":"9","author":"Chantong","year":"2012","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.jneuroim.2024.578364_bb0060","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1021\/ci300367a","article-title":"admetSAR: a comprehensive source and free tool for assessment of chemical ADMET properties","volume":"52","author":"Cheng","year":"2012","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.jneuroim.2024.578364_bb0065","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.exger.2017.07.004","article-title":"A cross-sectional comparison of brain glucose and ketone metabolism in cognitively healthy older adults, mild cognitive impairment and early Alzheimer\u2019s disease","volume":"107","author":"Croteau","year":"2018","journal-title":"Exp. Gerontol."},{"key":"10.1016\/j.jneuroim.2024.578364_bb0070","first-page":"650","article-title":"Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro","volume":"240","author":"de Gasparo","year":"1987","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.jneuroim.2024.578364_bb0075","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.bcp.2013.12.012","article-title":"Brain metabolic dysfunction at the core of Alzheimer\u2019s disease","volume":"88","author":"de la Monte","year":"2014","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jneuroim.2024.578364_bb0080","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028035","article-title":"Pathology of neurodegenerative diseases","volume":"9","author":"Dugger","year":"2017","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.jneuroim.2024.578364_bb0085","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1016\/j.cell.2022.09.030","article-title":"SYK coordinates neuroprotective microglial responses in neurodegenerative disease","volume":"185","author":"Ennerfelt","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.jneuroim.2024.578364_bb0090","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.7150\/ijbs.4679","article-title":"Interleukin-6, a major cytokine in the central nervous system","volume":"8","author":"Erta","year":"2012","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.jneuroim.2024.578364_bb0095","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/j.jacc.2013.04.086","article-title":"Safety and efficacy of Eplerenone in patients at high risk for hyperkalemia and\/or worsening renal function","volume":"62","author":"Eschalier","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.jneuroim.2024.578364_bb0100","doi-asserted-by":"crossref","first-page":"29932","DOI":"10.1074\/jbc.M110.131342","article-title":"A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule","volume":"285","author":"Fagart","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jneuroim.2024.578364_bb0105","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/glia.22437","article-title":"Toll-like receptor 4 is required for \u03b1-synuclein dependent activation of microglia and astroglia","volume":"61","author":"Fellner","year":"2013","journal-title":"Glia"},{"key":"10.1016\/j.jneuroim.2024.578364_bb0110","first-page":"307","article-title":"Microglial response to amyloid plaques in APPsw transgenic mice","volume":"152","author":"Frautschy","year":"1998","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.jneuroim.2024.578364_bb0115","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201809711","article-title":"Opposite microglial activation stages upon loss of PGRN or TREM2 result in reduced cerebral glucose metabolism","volume":"11","author":"G\u00f6tzl","year":"2019","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.jneuroim.2024.578364_bb0120","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20210542","article-title":"Activated microglia mitigate A\u03b2-associated tau seeding and spreading","volume":"218","author":"Gratuze","year":"2021","journal-title":"Journal of Experimental Medicine"},{"key":"10.1016\/j.jneuroim.2024.578364_bb0125","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1096\/fj.03-0969fje","article-title":"Novel immunosuppressive properties of interleukin-6 in dendritic cells: inhibition of NF-\u03baB binding activity and CCR7 expression","volume":"18","author":"Hegde","year":"2004","journal-title":"FASEB J."},{"key":"10.1016\/j.jneuroim.2024.578364_bb0130","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s12974-022-02496-w","article-title":"The role of toll-like receptors and neuroinflammation in Parkinson\u2019s disease","volume":"19","author":"Heidari","year":"2022","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.jneuroim.2024.578364_bb0135","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","article-title":"Neuroinflammation in Alzheimer\u2019s disease","volume":"14","author":"Heneka","year":"2015","journal-title":"The Lancet Neurology"},{"key":"10.1016\/j.jneuroim.2024.578364_bb0140","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3389\/fneur.2018.00162","article-title":"Hypertension and diagnosis of Parkinson\u2019s disease: a Meta-analysis of cohort studies","volume":"9","author":"Hou","year":"2018","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jneuroim.2024.578364_bb0145","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s13024-022-00588-y","article-title":"TREM2 dependent and independent functions of microglia in Alzheimer\u2019s disease","volume":"17","author":"Hou","year":"2022","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.jneuroim.2024.578364_bb0150","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s40256-017-0213-8","article-title":"Pitavastatin: a review in hypercholesterolemia","volume":"17","author":"Hoy","year":"2017","journal-title":"Am. J. Cardiovasc. Drugs"},{"key":"10.1016\/j.jneuroim.2024.578364_bb0155","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0197-0186(96)00078-2","article-title":"Cytokine-mediated neuronal apoptosis","volume":"30","author":"Hu","year":"1997","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.jneuroim.2024.578364_bb0160","first-page":"115","article-title":"The role of insulin receptor signaling in synaptic plasticity and cognitive function","volume":"33","author":"Huang","year":"2010","journal-title":"Chang Gung Med. J."},{"key":"10.1016\/j.jneuroim.2024.578364_bb0165","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S1567-5688(03)00003-5","article-title":"Statin inhibition of HMG-CoA reductase: a 3-dimensional view","volume":"4","author":"Istvan","year":"2003","journal-title":"Atherosclerosis Suppl."},{"key":"10.1016\/j.jneuroim.2024.578364_bb0170","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1016\/j.cell.2017.05.018","article-title":"A unique microglia type associated with restricting development of Alzheimer\u2019s disease","volume":"169","author":"Keren-Shaul","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.jneuroim.2024.578364_bb0175","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.15252\/embj.201796516","article-title":"The FTD -like syndrome causing TREM 2 T66M mutation impairs microglia function, brain perfusion, and glucose metabolism","volume":"36","author":"Kleinberger","year":"2017","journal-title":"EMBO J."},{"key":"10.1016\/j.jneuroim.2024.578364_bb0180","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ijcard.2015.05.127","article-title":"Safety profile of mineralocorticoid receptor antagonists: spironolactone and eplerenone","volume":"200","author":"Lainscak","year":"2015","journal-title":"Int. J. Cardiol."},{"key":"10.1016\/j.jneuroim.2024.578364_bb0185","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/00005344-200408000-00010","article-title":"Pharmacokinetics and steady-state bioequivalence of Treprostinil sodium (Remodulin\u00ae) administered by the intravenous and subcutaneous route to Normal volunteers","volume":"44","author":"Laliberte","year":"2004","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.jneuroim.2024.578364_bb0190","doi-asserted-by":"crossref","first-page":"152","DOI":"10.2174\/1570159X18666200729093724","article-title":"The links between cardiovascular diseases and Alzheimer\u2019s disease","volume":"19","author":"Leszek","year":"2020","journal-title":"CN"},{"key":"10.1016\/j.jneuroim.2024.578364_bb0195","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/bcpt.13305","article-title":"The prostacyclin analogue treprostinil in the treatment of pulmonary arterial hypertension","volume":"126","author":"Lindegaard Pedersen","year":"2020","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.jneuroim.2024.578364_bb0200","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/glia.1072","article-title":"Inflammatory repertoire of Alzheimer\u2019s disease and nondemented elderly microglia in vitro","volume":"35","author":"Lue","year":"2001","journal-title":"Glia"},{"key":"10.1016\/j.jneuroim.2024.578364_bb0205","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/j.1365-2125.2006.02609.x","article-title":"The implications of a growing evidence base for drug use in elderly patients. Part 1. Statins for primary and secondary cardiovascular prevention","volume":"61","author":"Mangoni","year":"2006","journal-title":"Brit J Clinical Pharma"},{"key":"10.1016\/j.jneuroim.2024.578364_bb0210","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/01.jnen.0000240472.43038.27","article-title":"Hematopoietic prostaglandin D synthase and DP1 receptor are selectively upregulated in microglia and astrocytes within senile plaques from human patients and in a mouse model of Alzheimer disease","volume":"66","author":"Mohri","year":"2007","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.jneuroim.2024.578364_bb0215","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3389\/fnins.2020.00213","article-title":"Neurodegenerative diseases \u2013 is metabolic deficiency the root cause?","volume":"14","author":"Muddapu","year":"2020","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.jneuroim.2024.578364_bb0220","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.atherosclerosis.2009.12.009","article-title":"Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia","volume":"210","author":"Ose","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jneuroim.2024.578364_bb0225","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.clinbiochem.2019.04.001","article-title":"Neuro-inflammation and anti-inflammatory treatment options for Alzheimer\u2019s disease","volume":"72","author":"Ozben","year":"2019","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.jneuroim.2024.578364_bb0230","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1172\/JCI119812","article-title":"Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages","volume":"100","author":"Pahan","year":"1997","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jneuroim.2024.578364_bb0235","first-page":"57","article-title":"Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS\u2606","volume":"21","author":"Petrovitch","year":"2000","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.jneuroim.2024.578364_bb0240","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2024.578364_bb0245","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.108.778811","article-title":"Serum potassium and clinical outcomes in the eplerenone post\u2013acute myocardial infarction heart failure efficacy and survival study (EPHESUS)","volume":"118","author":"Pitt","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.jneuroim.2024.578364_bb0250","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.metabol.2016.05.018","article-title":"Role of metabolism in neurodegenerative disorders","volume":"65","author":"Procaccini","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.jneuroim.2024.578364_bb0255","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S1474-4422(05)70141-1","article-title":"The age-dependent relation of blood pressure to cognitive function and dementia","volume":"4","author":"Qiu","year":"2005","journal-title":"The Lancet Neurology"},{"key":"10.1016\/j.jneuroim.2024.578364_bb0260","doi-asserted-by":"crossref","first-page":"9293","DOI":"10.1074\/jbc.M113.455816","article-title":"EP2 receptor signaling pathways regulate classical activation of microglia","volume":"288","author":"Quan","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jneuroim.2024.578364_bb0265","doi-asserted-by":"crossref","first-page":"33344","DOI":"10.1074\/jbc.M203567200","article-title":"The prostacyclin analogue Treprostinil blocks NF\u03baB nuclear translocation in human alveolar macrophages","volume":"277","author":"Raychaudhuri","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jneuroim.2024.578364_bb0270","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1002\/eji.1830190815","article-title":"Monokine production by microglial cell clones","volume":"19","author":"Righi","year":"1989","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.jneuroim.2024.578364_bb0275","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.7150\/ijbs.4989","article-title":"IL-6 trans-signaling via the soluble IL-6 receptor: importance for the pro-inflammatory activities of IL-6","volume":"8","author":"Rose-John","year":"2012","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.jneuroim.2024.578364_bb0280","doi-asserted-by":"crossref","first-page":"3100","DOI":"10.1073\/pnas.0308724101","article-title":"Role for neuronal insulin resistance in neurodegenerative diseases","volume":"101","author":"Schubert","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jneuroim.2024.578364_bb0285","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.jneuroim.2024.578364_bb0290","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1161\/HYPERTENSIONAHA.111.178962","article-title":"Midlife blood pressure, plasma \u03b2-amyloid, and the risk for Alzheimer disease: the Honolulu Asia aging study","volume":"59","author":"Shah","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.jneuroim.2024.578364_bb0295","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1021\/ci100104j","article-title":"Estimation of ADME properties with substructure pattern recognition","volume":"50","author":"Shen","year":"2010","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.jneuroim.2024.578364_bb0300","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1084\/jem.20190980","article-title":"Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model","volume":"216","author":"Shi","year":"2019","journal-title":"Journal of Experimental Medicine"},{"key":"10.1016\/j.jneuroim.2024.578364_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2023.578031","article-title":"Genome-wide identification of murine interferon genes in microglial-mediated neuroinflammation in Alzheimer\u2019s disease","volume":"375","author":"Shippy","year":"2023","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2024.578364_bb0310","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12974-020-01948-5","article-title":"\u03b2-Hydroxybutyrate inhibits inflammasome activation to attenuate Alzheimer\u2019s disease pathology","volume":"17","author":"Shippy","year":"2020","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.jneuroim.2024.578364_bb0315","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s12864-022-08417-8","article-title":"Transcriptional response of murine microglia in Alzheimer\u2019s disease and inflammation","volume":"23","author":"Shippy","year":"2022","journal-title":"BMC Genomics"},{"key":"10.1016\/j.jneuroim.2024.578364_bb0320","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1164\/ajrccm.165.6.2106079","article-title":"Continuous subcutaneous infusion of Treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial","volume":"165","author":"Simonneau","year":"2002","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.jneuroim.2024.578364_bb0325","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/1742-2094-9-115","article-title":"A comparative review of cell culture systems for the study of microglial biology in Alzheimer\u2019s disease","volume":"9","author":"Stansley","year":"2012","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.jneuroim.2024.578364_bb0330","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1177\/2047487312437326","article-title":"Pitavastatin demonstrates long-term efficacy, safety and tolerability in elderly patients with primary hypercholesterolaemia or combined (mixed) dyslipidaemia","volume":"20","author":"Stender","year":"2013","journal-title":"Eur J Prev Cardiolog"},{"key":"10.1016\/j.jneuroim.2024.578364_bb0335","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.pneurobio.2013.04.004","article-title":"Mitochondrial dysfunction and oxidative stress in Parkinson\u2019s disease","volume":"106\u2013107","author":"Subramaniam","year":"2013","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.jneuroim.2024.578364_bb0340","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.cell.2017.07.023","article-title":"TREM2 maintains microglial metabolic fitness in Alzheimer\u2019s disease","volume":"170","author":"Ulland","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.jneuroim.2024.578364_bb0345","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2024.578364_bb0350","doi-asserted-by":"crossref","first-page":"2953","DOI":"10.3390\/ijms22062953","article-title":"MicroRNAs, Parkinson\u2019s disease, and diabetes mellitus","volume":"22","author":"Wang","year":"2021","journal-title":"IJMS"},{"key":"10.1016\/j.jneuroim.2024.578364_bb0355","first-page":"136","article-title":"Role of pro-inflammatory cytokines released from microglia in Alzheimer\u2019s disease","volume":"3","author":"Wang","year":"2015","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.jneuroim.2024.578364_bb0360","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1084\/jem.20151948","article-title":"TREM2-mediated early microglial response limits diffusion and toxicity of amyloid plaques","volume":"213","author":"Wang","year":"2016","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jneuroim.2024.578364_bb0365","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1016\/j.cell.2022.09.033","article-title":"TREM2 drives microglia response to amyloid-\u03b2 via SYK-dependent and -independent pathways","volume":"185","author":"Wang","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.jneuroim.2024.578364_bb0370","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3390\/cells11020267","article-title":"Selective interactions of mouse Melanocortin receptor accessory proteins with somatostatin receptors","volume":"11","author":"Wang","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.jneuroim.2024.578364_bb0375","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1056\/NEJMoa2008470","article-title":"Inhaled Treprostinil in pulmonary hypertension due to interstitial lung disease","volume":"384","author":"Waxman","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jneuroim.2024.578364_bb0380","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.bcp.2012.03.012","article-title":"Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: Treprostinil is a potent DP1 and EP2 agonist","volume":"84","author":"Whittle","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jneuroim.2024.578364_bb0385","doi-asserted-by":"crossref","first-page":"D1074","DOI":"10.1093\/nar\/gkx1037","article-title":"DrugBank 5.0: a major update to the DrugBank database for 2018","volume":"46","author":"Wishart","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.jneuroim.2024.578364_bb0390","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1741-7015-5-20","article-title":"Simvastatin is associated with a reduced incidence of dementia and Parkinson\u2019s disease","volume":"5","author":"Wolozin","year":"2007","journal-title":"BMC Med."},{"key":"10.1016\/j.jneuroim.2024.578364_bb0395","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/eurjhf\/hfp023","article-title":"Anti-inflammatory effects of eplerenone on viral myocarditis","volume":"11","author":"Xiao","year":"2009","journal-title":"European J of Heart Fail"},{"key":"10.1016\/j.jneuroim.2024.578364_bb0400","article-title":"The impact of systemic inflammation on Alzheimer\u2019s disease pathology","volume":"12","author":"Xie","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jneuroim.2024.578364_bb0405","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.freeradbiomed.2016.04.200","article-title":"Energy metabolism and inflammation in brain aging and Alzheimer\u2019s disease","volume":"100","author":"Yin","year":"2016","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.jneuroim.2024.578364_bb0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109112","article-title":"RIPK1 activation mediates neuroinflammation and disease progression in multiple sclerosis","volume":"35","author":"Zelic","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.jneuroim.2024.578364_bb0415","doi-asserted-by":"crossref","first-page":"702","DOI":"10.4049\/jimmunol.178.2.702","article-title":"Prostaglandin I2 analogs inhibit Proinflammatory cytokine production and T cell stimulatory function of dendritic cells","volume":"178","author":"Zhou","year":"2007","journal-title":"J. Immunol."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572824000821?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572824000821?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T20:34:23Z","timestamp":1717619663000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572824000821"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":83,"alternative-id":["S0165572824000821"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2024.578364","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mitigation of CXCL10 secretion by metabolic disorder drugs in microglial-mediated neuroinflammation","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2024.578364","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"578364"}}